The Incidence and Clinical Outcome of YMDD Mutants in Hepatitis B Surface Antigen-Positive Renal Allograft Recipients After Prolonged Lamivudine Therapy

Transplantation Proceedings

Volumn 39, Issue 10, 2007, Pages 3121-3126

  Gwak, G Y ^a   Huh, W ^a   Lee, D H ^a   Choi, M S ^a   Lee, J H ^a   Koh, K C ^a   Kim, S J ^a   Joh, J W ^a   Oh, H Y ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; HEPATITIS B SURFACE ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DISEASE COURSE; DISEASE SEVERITY; DRUG POTENCY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; KIDNEY ALLOGRAFT; LIVER DYSFUNCTION; LIVER FAILURE; MALE; MUTANT; NONHUMAN; OUTCOME ASSESSMENT; PATIENT MONITORING; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; VIREMIA; VIRUS REPLICATION; VIRUS STRAIN; WILD TYPE;

ADULT; ANTIVIRAL AGENTS; DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL PROTEINS;

EID: 37049031228     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.06.081     Document Type: Article

References (39)

1. Pirson Y., Alexandre G.P.J., and Van Ypersele S.C. Long-term effects of hbs antigenemia on patient survival after renal transplantation. N Engl J Med 296 (1977) 194
2. Harnett J.D., Zeldis J.B., Parfrey P.S., et al. Hepatitis B disease in dialysis and transplant patients. Further epidemolonic and serologic studies. Transplantation 44 (1987) 369
3. Rao K.V., Kasiske B.L., and Andersen W.R. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis-B positive and B-negative renal transplant recipients. Transplantation 51 (1991) 391
4. Mathurin P., Mouquet C., Poynard T., et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 29 (1999) 257
5. Maynard J.E. Hepatitis B: global importance and need for control. Vaccine 8 suppl (1990) S18
6. Bang B.K., Yang C.W., Yoon S.A., et al. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in iclosporin-treated renal allograft recipients. Nephron 70 (1995) 397
7. Parfrey P.S., Forbes R.D.C., Hutchinson T.A., et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation 39 (1985) 610
8. Fornairon S., Pol S., Legendre C., et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 62 (1996) 297
9. Lai C.L., Chien R.N., Leung N.W., et al., Asia hepatitis Lamuvidine Study Group. A one-year trial of lamuvidine for chronic hepatitis B. N Engl J Med 339 (1998) 61
10. Magnone M., Holley J.L., Shapiro R., et al. Interferon-alpha-induced acute renal allograft rejection. Transplantation 59 (1995) 1068
11. Rostaing L., Henry S., Cisterne J.M., et al. Efficacy and safety of lamuvidine on replication of recurrent hepatitis B after cadaveric renal transplantation. Transplantation 64 (1997) 1624
12. Jung Y.O., Lee Y.S., Yang W.S., et al. Treatment of chronic hepatitis B with lamuvidine in renal transplant recipients. Transplantation 66 (1998) 733
13. Chan T.M., Wu P.C., Li F.K., et al. Treatment of fibrosing cholestatic hepatitis with lamuvidine. Gastroenterology 115 (1998) 177
14. Park S.K., Yang W.S., Lee Y.S., et al. Outcome of renal transplantation in hepatitis B surface antigen-positive patients after introduction of lamuvidine. Nephrol Dial Transplant 16 (2001) 2222
15. Kim J.A., Huh W., Lee K.W., et al. Cadaveric renal transplantation in hepatitis B antigen-positive recipients using hepatitis B-antigen-positive donors with lamuvidine treatment. Transplant Proc 36 (2004) 1434
16. Tipples G.A., Ma M.M., Fischer K.P., et al. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamuvidine in vivo. Hepatology 24 (1996) 714
17. Liaw Y.F., Leung N.W., Chang T.T., et al., Asia Hepatitis B Lamuvidine Group. Effects of extended lamuvidine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119 (2000) 172
18. Melegari M., Scaglioni P.P., and Wands J.R. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27 (1998) 628
19. Hoofnagle J.H., Dusheiko G.M., Schafer D.F., et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96 (1982) 447
20. Yeo W., Chan P.K.S., Zhong S., et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62 (2000) 299
21. Yeo W., Lam K.C., Zee B., et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15 (2004) 1661
22. Yeo W., and Johnson P.J. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 43 (2006) 209
23. Lau G.K., He M.L., Fong D.Y., et al. Preemptive use of lamuvidine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 36 (2002) 702
24. Lau G.K., Yiu H.H., Fong D.Y., et al. Early is superior to deferred preemptive lamuvidine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125 (2003) 1742
25. Rossi G., Pelizzari A., Motta M., et al. Primary prophylaxis with lamuvidine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 115 (2001) 58
26. Chan T.M., Fang G.X., Tang C.S., et al. Preemptive lamuvidine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 36 (2002) 1246
27. Lok A.S., and McMahon B.J. Chronic hepatitis B. Hepatology 45 (2007) 507
28. Perrillo R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 120 (2001) 1009
29. Leung N.W., Lai C.L., Chang T.T., et al. Extended lamuvidine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33 (2001) 1527
30. Xiong X., Flores C., Yang H., et al. Mutations in hepatitis B DNA polymerase associated with resistance to lamuvidine do not confer resistance to adefovir in vitro. Hepatology 28 (1998) 1669
31. Cote P.J., Korba B.E., Baldwin B., et al. Immunosuppression with cyclosporine during the incubation period of experimental woodchuck hepatitis virus infection increases the frequency of chronic infection in adult woodchucks. J Infect Dis 166 (1992) 628
32. Tur-Kaspa R., Burk R.D., Shaul Y., et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 83 (1986) 1627
33. Tur-Kaspa R., Shaul Y., Moore D.D., et al. The glucocorticoid receptor recognized a specific nucleotide sequence in hepatitis B virus DNA causing increased activity of the HBV enhancer. Virology 167 (1988) 630
34. Chou C.K., Wang L.H., Lin H.M., et al. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 16 (1992) 13
35. Meuleman P., Libbrecht L., Wieland S., et al. Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol 80 (2006) 2797
36. Marcellin P., Chang T.T., Lim S.G., et al. Adefovir dipivoxil for the treatment of hepatitis e antigen-positive chronic hepatitis B. N Engl J Med 348 (2003) 808
37. Chang T.T., Gish R.G., Man R.D., et al. A comparison of entecavir and lamuvidine for HBeAg-positive chronic hepatitis B. N Engl J Med 354 (2006) 1001
38. Colonno R.J., Rose R., Baldick C.J., et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 44 (2006) 1656
39. Lai C.L., Leung N., Teo E.K., et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129 (2005) 528